ライフサイエンスコーパス: atrial septal defect

1 alvular aortic stenosis, and 2.8% for primum atrial septal defect.

2 gical approaches for simple lesions, such as atrial septal defect.

3 One infant had an atrial septal defect.

4 undergo surgical repair of an ostium primum atrial septal defect.

5 22 patients and 10 control subjects with an atrial septal defect.

6 of the anomalous pulmonary veins through the atrial septal defect.

7 er responding to surgical closure of a large atrial septal defect.

8 nt with tricuspid atresia and large secundum atrial septal defect.

9 in a large family with dominantly inherited atrial septal defect.

10 ccluder for percutaneous closure of secundum atrial septal defects.

11 n of the great arteries, and ventricular and atrial septal defects.

12 heart syndrome but inversely associated with atrial septal defects.

13 fety and efficacy of device closure of large atrial septal defects.

14 interaction affect muscular ventricular and atrial septal defects.

15 days sooner, P<0.001) and noncritical CHDs (atrial septal defects [12.4 months sooner, P=0.037], ven

16 rmed on 9 kindreds with familial CHD, 4 with atrial septal defects, 2 with patent ductus arteriosus,

17 ich ventricular septal defects (22/47, 47%), atrial septal defects (20/47, 43%), patent ductus arteri

18 ancreatic insufficiency (67%), chorea (64%), atrial septal defect (24%), microcephaly (17%), paragang

19 Principal features of IART circuits were atrial septal defect (4 patients), atriotomy (3 patients

20 ect, 3.3%; and 8) urinary tract infection in atrial septal defect, 6.4%.

21 5+/-14 years) with PHT and associated CHD (9 atrial septal defect, 7 ventricular septal defect, 4 tra

22 tion of the great arteries (8%), ventricular/atrial septal defects (8%), left ventricular outflow obs

23 Final QIs included: 8 for atrial septal defects; 9 for aortic coarctation; 12 for

24 In the presence of an acute atrial septal defect, a Qp/Qs ratio of 1.3+/-0.2 was mea

25 including aortic coarctation, ventricular or atrial septal defect, abnormal mitral valve, aortic root

26 ere at highest risk of IE in comparison with atrial septal defects (adjusted rate ratio, 95% confiden

27 phisms that confer greater susceptibility to atrial septal defect and atrioventricular septal defects

28 SC in patients with a superior sinus venosus atrial septal defect and could be a feasible alternative

29 epilepticus, congestive heart failure due to atrial septal defect and hypernatremic dehydration due t

30 monary stenosis in 2 and subaortic membrane, atrial septal defect and mitral regurgitation in 1 patie

31 re moderate to large VSD in two patients and atrial septal defect and unlimited differential diagnosi

32 quarter of affected individuals, as well as atrial septal defect and ventricular septal defect.

33 or not severe, excluding cases with isolated atrial septal defect and/or patent foramen ovale.

34 iac malformations, including ventricular and atrial septal defects and a thin ventricular myocardium.

35 iations between carbon monoxide and isolated atrial septal defects and between ozone and isolated ven

36 athways may contribute to the development of atrial septal defects and bicuspid aortic valves.

37 onsistent in magnitude were detected between atrial septal defects and bromoform (aOR = 1.56; 95% CI:

38 Most cases of atrial septal defects and cardiomyopathy are not associa

39 nd, hence, is a candidate causative gene for atrial septal defects and cardiomyopathy.

40 domain, p.G115W, was identified in familial atrial septal defects and demonstrated decreased transac

41 tion factor, were reported to cause secundum atrial septal defects and result in atrioventricular (AV

42 al defect device for use in multifenestrated atrial septal defects and the fenestrated atrial septal

43 Antidiastole of coronary heart disease, atrial septal defect, and atrial fibrillation are made,

44 n autosomal dominant skeletal dysplasia with atrial septal defects, and familial total anomalous pulm

45 D (ie, excluding ventricular septal defects, atrial septal defects, and pulmonary valve stenosis) occ

46 duodenal atresia/stenosis (aOR = 2.48), and atrial septal defect (aOR = 1.37).

47 were positively associated with the risks of atrial septal defect (aORs ranging from 1.29 to 2.17), p

48 these pollutants and daily risks of secundum atrial septal defect, aortic coarctation, hypoplastic le

49 Two separate ostium secundum atrial septal defects are a challenging substrate for de

50 Most children with isolated atrial septal defects are free of symptoms, but the rate

51 Atrial septal defects are the third most common type of

52 defects (aRR, 0.85; 95% CI, 0.75-0.96), and atrial septal defects (aRR, 0.82; 95% CI, 0.69-0.95) but

53 370), left-sided lesions (n = 160), secundum atrial septal defect (ASD) (n = 71), and Ebstein's malfo

54 ht atrium to the right ventricle and both an atrial septal defect (ASD) and a ventricular septal defe

55 r (RV) volume after transcatheter closure of atrial septal defect (ASD) and to investigate factors th

56 Only one atrial septal defect (ASD) and two patent ductus arterio

57 We compared administrative data for atrial septal defect (ASD) and ventricular septal defect

58 efine types and significance of isolated and atrial septal defect (ASD) associated PAPVC detected by

59 to aspirin for 3 months after transcatheter atrial septal defect (ASD) closure results in a lower in

60 e attacks is a complication of transcatheter atrial septal defect (ASD) closure.

61 Familial atrial septal defect (ASD) has previously been attribute

62 x 10(-)(7)) with the risk of ostium secundum atrial septal defect (ASD) in the discovery cohort (N =

63 Secundum atrial septal defect (ASD) is a common congenital heart

64 Secundum atrial septal defect (ASD) is the most common adult cong

65 A variety of transcatheter atrial septal defect (ASD) occluders are currently in us

66 Sinus venosus atrial septal defect (ASD) was the most common associate

67 eptal occluder (ASO) for closure of secundum atrial septal defect (ASD) with surgical closure.

68 MYH6 can cause an autosomal dominant form of atrial septal defect (ASD), whereas others have identifi

69 eptal occluder (HSO) with surgical repair of atrial septal defect (ASD).

70 owing isolated procedures: device closure of atrial septal defect (ASD); device closure of patent duc

71 n = 20), obesity (OB, n = 20), and corrected atrial septal defect (ASD, n = 25) as controls.

72 use of permanent synthetic implants to close atrial septal defects (ASD) and patent foramen ovale (PF

73 form transcatheter closures of secundum type atrial septal defects (ASD) and to assess ASD size and c

74 m in the embryo and persistent ostium primum atrial septal defects (ASD) in approximately 20% of adul

75 to MSX1 and STX18, has been associated with atrial septal defects (ASD) in multiple European and Chi

76 Atrial septal defects (ASD) show an open communication b

77 ntan physiology and 12 control patients with atrial septal defects (ASD) that underwent cardiac cathe

78 Transcatheter closure of secundum atrial septal defects (ASD) using the Amplatzer septal o

79 phy (ICE) in guiding percutaneous closure of atrial septal defects (ASD).

80 g (PH(20)), may be observed in patients with atrial septal defects (ASD).

81 attractive therapeutic option for congenital atrial septal defects (ASD).

82 pidemiologic analyses of five birth defects (atrial septal defect [ASD], ventricular septal defect [V

83 Fallot, transposition of the great arteries, atrial septal defects [ASD], aortic arch defects, and si

84 While atrial septal defects (ASDs) and atrial fibrillation (AF

85 fourth generation buttoned device in dosing atrial septal defects (ASDs) and to test the hypothesis

86 d to become a mainstay of treatment for many atrial septal defects (ASDs) and ventricular septal defe

87 Atrial septal defects (ASDs) are a common human congenit

88 generations of closure devices for secundum atrial septal defects (ASDs) at a single institution.

89 tional dysregulation leads to development of atrial septal defects (ASDs) at high frequency.

90 Atrial septal defects (ASDs) can result from haploinsuff

91 rnelia de Lange syndrome-associated secundum atrial septal defects (ASDs) caused by NIPBL mutations,

92 Transcatheter closure of atrial septal defects (ASDs) has been feasible and succe

93 was to quantitate shunt flow volumes through atrial septal defects (ASDs) in a chronic animal model w

94 Atrial septal defects (ASDs) represent the most common c

95 spected anomalous pulmonary veins (APVs) and atrial septal defects (ASDs) using fast cine magnetic re

96 buttoned device for transcatheter closure of atrial septal defects (ASDs).

97 sthesis for percutaneous closure of secundum atrial septal defects (ASDs).

98 went surgical correction of an ostium primum atrial septal defect at our institution at a mean age of

99 en <15 years) with large, isolated, secundum atrial septal defects (balloon-stretched diameter >/=34

100 mmon pediatric conditions, including asthma, atrial septal defects, bronchiolitis, diabetic ketoacido

101 septal defect (SVASD) differs from secundum atrial septal defect by its atrial septal location and i

102 ients undergoing the surgical creation of an atrial septal defect by the Blalock-Hanlon technique.

103 Atrial septal defects call for tertiary expertise where

104 ven patients (6%) in the pitavastatin group (atrial septal defect, chronic obstructive pulmonary dise

105 alve procedure (9%), patent foramen ovale or atrial septal defect closure (23%), cardiac metastasecto

106 Between 2008 and 2012, atrial septal defect closure with the AMPLATZER Septal O

107 and frequent concomitant procedures such as atrial septal defect closure, arrhythmia surgery (the ma

108 enomic analyses of probands with heterotaxy, atrial septal defects, conotruncal, and left ventricular

109 dure (120 versus 52 minutes; P=0.005) and to atrial septal defect creation (55 versus 29 minutes; P=0

110 s with HLH-IAS, hybrid LAD allows for faster atrial septal defect creation, has a higher technical su

111 Atrial septal defect device closure decreased Qp from 6.

112 already well-established techniques such as atrial septal defect device closure.

113 ed Amplatzer Ductal Occluder, the cribriform atrial septal defect device for use in multifenestrated

114 ed atrial septal defects and the fenestrated atrial septal defect device.

115 ar that evaluated the safety and efficacy of atrial septal defect devices, patent ductus occluders, a

116 oninvasive procedure to create or enlarge an atrial septal defect for the treatment of neonates with

117 Percutaneous treatment of inter-atrial septal defects has undergone exponential growth i

118 sions, with the lowest risk in patients with atrial septal defects (HR, 1.36 [95% CI, 1.19-1.55]).

119 obese women had significantly higher ORs for atrial septal defects, hypoplastic left heart syndrome,

120 g Gibbon's historic successful closure of an atrial septal defect in 1953 with his heart-lung machine

121 tachycardia (AT) after SR-CHD were studied (atrial septal defect in 6, tetralogy of Fallot in 4, and

122 m was suspected in four, or to close a large atrial septal defect in four) could be contacted.

123 l lymphopenia, intermittent neutropenia, and atrial septal defects in 3 members of a consanguineous k

124 pathophysiology, treatment, and outcomes of atrial septal defects in children and adult patients in

125 correction (CSC) of a superior sinus venosus atrial septal defect is an alternative to surgery in sel

126 Atrial septal defect is one of the most common forms of

127 BI in patients with 2 atrial septal defects is helpful in defining 1- versus 2

128 .I263V mutation in TLL1 was identified in an atrial septal defects kindred and is predicted to affect

129 ts with repaired "simple" lesions such as an atrial septal defect may not have normal survival if the

130 AV cushion defects including atrial septal defect, membranous VSD, and thickened valv

131 patients underwent repair of a secundum-type atrial septal defect (n=12) or patent foramen ovale (n=5

132 The most common CHD type was atrial septal defect (n=78).

133 microm in aerodynamic diameter and isolated atrial septal defects (odds ratio = 2.27, 95% confidence

134 We identified a new locus linked with atrial septal defect on chromosome 14q12 in a large fami

135 e more severe than isolated PAPVC-associated atrial septal defect only.

136 uals who had had transcatheter closure of an atrial septal defect or patent foramen ovale to assess h

137 eatinine > or =2 mg/dL (OR 4.7), restrictive atrial septal defect (OR 2.7) and, in staged surgery, at

138 e an embryologic basis for the prevalence of atrial septal defects (ostium primum and secundum), vent

139 No children with secundum atrial septal defect, patent ductus arteriosus, or pulmo

140 likely to be diagnosed via imaging (secundum atrial septal defect, patent ductus arteriosus, ventricu

141 A milder form of atrial septal defect, patent foramen ovale (PFO), exists

142 uch as the transcatheter closure of secundum atrial septal defects, patent foramen ovale, patent duct

143 tricular septal defect (1.07, 0.95 to 1.21), atrial septal defect/patent foramen ovale (1.04, 0.88 to

144 overall, ventricular septal defect, secundum atrial septal defect/patent foramen ovale, neural tube d

145 abilities and genetic and molecular basis of atrial septal defects remain unclear.

146 ed patients immediately prior to an elective atrial septal defect repair procedure.

147 ting surgery for congenital heart disease (9 atrial septal defect repair, 4 Fontan, 2 Mustard, 2 Senn

148 eak (prior Mustard procedure), closure of an atrial septal defect, repair of partial anomalous pulmon

149 t of the TARP syndrome, talipes equinovarus, atrial septal defect, Robin sequence, and persistent lef

150 Prevalence of the diagnosis of secundum atrial septal defect rose from 2.3 per mille in 2000-200

151 tations, but not a mutation causing secundum atrial septal defects (S52F), demonstrated impaired prot

152 Periostin null mice exhibit atrial septal defects, structural abnormalities of the A

153 Sinus venosus atrial septal defect (SVASD) differs from secundum atria

154 The superior sinus venosus atrial septal defect (SVASD) is characterized by deficie

155 Covered stent correction for a sinus venosus atrial septal defect (SVASD) was first performed in 2009

156 g man with IAA associated with sinus venosus atrial septal defect (SVD) and partial anomalous pulmona

157 Sinus venosus atrial septal defect (SVD) is underdiagnosed with transt

158 of great vessels, ventricular septal defect, atrial septal defect, tetralogy of Fallot, coarctation o

159 g these tools, specifically in patients with atrial septal defects, tetralogy of Fallot, single ventr

160 mid-to-long-term data for device closure of atrial septal defects, the incidence of late cardiac ero

161 ccluder for Percutaneous Closure of Secundum Atrial Septal Defects; this study was approved by the Fo

162 reports the pilot in vivo study to create an atrial septal defect through the use of extracardiac app

163 ting on children after closure of a secundum atrial septal defect through the use of surgery (n=26) o

164 y the type of defect, from a low of 4.7% for atrial septal defects to a high of 28% for hypoplastic l

165 2 patients without prior diagnosis of PFO or atrial septal defect undergoing surgery at the Cleveland

166 Closure of large atrial septal defects using the Amplatzer device is safe

167 Sudden death after surgery for atrial septal defect, ventricular septal defect, tetralo

168 ry for 2 cohorts: (1) all patients with CHD (atrial septal defect, ventricular septal defect, tetralo

169 An atrial septal defect was created in dogs by blade septos

170 An atrial septal defect was present in 67 patients (88%) pr

171 In 9 of 10 canines, an atrial septal defect was produced, and shunting across t

172 A large atrial septal defect was the only structural heart disea

173 congenital cardiac malformations other than atrial septal defect were excluded.

174 Under real-time ultrasound guidance, atrial septal defects were successfully created with ext

175 s decreased between 1990 and 2011 except for atrial septal defects, which increased significantly.

176 spective study comprising 20 patients with 2 atrial septal defects who underwent device closure.

177 Closure of atrial septal defect with the AMPLATZER Septal Occluder

178 Pathology of the hearts showed atrial septal defects with minimal damage to surrounding